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Abstract
Objective:  To  investigate  hepatocellular  carcinoma  (HCC)  incidence,  risk  factors  and  the  per-
formance  of  baseline  REACH-B  risk  score  in  a  Portuguese  chronic  hepatitis  B  (CHB)  population
on antiviral  therapy.
Methods:  Retrospective  study  of  CHB  patients  who  were  treated  with  tenofovir  or  entecavir
for at  least  12  months.  Multivariate  analysis  was  performed  to  identify  factors  associated  with
HCC. The  Kaplan--Meier  method  was  used  to  estimate  the  cumulative  incidence  of  HCC  at  1,  3
and 5  years  on  therapy.  The  performance  of  the  REACH-B  score  at  baseline  was  assessed.
Results: One  hundred  and  twenty  patients  initiated  nucleos(t)ide  analogs  (NUC)  therapy
(age, 47  ±  14  years-old;  83  male;  11%  had  cirrhosis;  71%  tenofovir;  73%  HBeAg-negative;  61%
treatment-naïve).  After  a  median  time  under  NUC  of  39  months,  9  patients  (7.5%)  developed
HCC. The  calculated  cumulative  incidence  rates  of  HCC  at  1,  3  and  5  years  on  therapy  were
5.1%, 7.3%  and  8.8%,  respectively.  Independent  predictors  for  HCC  occurrence:  age  and  cirrho-
sis at  baseline.  Diagnostic  accuracy  of  baseline  REACH-B  score  in  predicting  HCC  development:
AUC 0.738,  95%CI:  0.521--0.955.  The  cutoff  value  of  8  points  had  a  sensitivity,  speciﬁcity,  pos-
itive predictive  value  and  negative  predictive  value  of  75%,  52%,  6%  and  98%,  respectively  in
predicting  HCC  occurrence  during  therapy.
Conclusions:  Older  age  and  cirrhosis  at  baseline  were  independent  predictors  for  HCC  develop-
ment. Discriminatory  performance  of  baseline  REACH-B  score  was  limited.
© 2016  Sociedade  Portuguesa  de  Gastrenterologia.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is
an open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).∗ Corresponding author.
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Carcinoma  Hepatocelular  em  Doentes  Com  Infecc¸ão Crónica  pelo  Vírus  da  Hepatite  B
Sob  Análogos  dos  Nucleós(t)idos  de  3a Gerac¸ão:  Factores  de  Risco  e  o  Desempenho  de
um  Score  de  Risco
Resumo
Objectivo:  Estudar  a  incidência  de  carcinoma  hepatocelular  (CHC),  factores  de  risco  e  desem-
penho do  score  REACH-B  (basal)  numa  populac¸ão  portuguesa  de  doentes  com  infecc¸ão  crónica
pelo vírus  da  hepatite  B  (VHB)  sob  análogos  dos  nucleós(t)idos  de  3a gerac¸ão  (NUC).
Métodos:  Estudo  retrospetivo  de  uma  coorte  de  doentes  com  infecc¸ão  crónica  pelo  VHB  tratados
com tenofovir  ou  entecavir  durante  pelo  menos  12  meses.  Foi  realizada  uma  análise  multivari-
ada para  identiﬁcar  os  factores  associados  ao  desenvolvimento  de  CHC.  Através  do  método
de Kaplan-Meier  foi  estimada  a  incidência  cumulativa  de  CHC  ao  ﬁnal  de  1,  3  e  5  anos  sob
terapêutica  antiviral.
Resultados:  Cento  e  vinte  doentes  iniciaram  terapêutica  com  um  NUC  (idade,  47  ±  14  anos;
83 género  masculino;  11%  com  cirrose;  71%  tenofovir;  73%  AgHBe-negativo;  61%  naïves).  Após
um período  mediano  de  39  meses  sob  NUC,  9  doentes  (7.5%)  desenvolveram  CHC.  A  incidên-
cia cumulativa  de  CHC  ao  ﬁnal  de  1,  3  e  5  anos  sob  terapêutica  antiviral  foi  de  5,1%,  7,3%  e
8,8%, respetivamente.  Preditores  independentes  de  CHC:  idade  e  cirrose  diagnosticada  pre-
viamente  ao  início  da  terapêutica  antiviral.  Precisão  diagnóstica  da  aplicac¸ão  basal  do  score
REACH-B para  predizer  CHC:  AUC  0,738,  95%CI:  0,521-0,955.  A  utilizac¸ão  do  valor  cutoff  de
8 pontos  produziu  uma  sensibilidade,  especiﬁcidade,  valor  preditivo  positivo  e  valor  preditivo
negativo de  75%,  52%,  6%  e  98%,  respetivamente  na  predic¸ão  de  ocorrência  de  CHC  durante  o
tratamento.
Conclusões: Idade  avanc¸ada  e  a  presenc¸a  de  cirrose  diagnosticada  previamente  ao  início  da
terapêutica  antiviral  demonstraram-se  preditores  independentes  para  o  desenvolvimento  de
CHC. O  poder  discriminatório  basal  do  score  REACH-B  foi  limitado.
© 2016  Sociedade  Portuguesa  de  Gastrenterologia.  Publicado  por  Elsevier  Espan˜a,  S.L.U.  Este
e´ um  artigo  Open  Access  sob  uma  licenc¸a  CC  BY-NC-ND  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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c. Introduction
t  is  believed  that  persistent  viral  replication  together  with
he  resulting  liver  injury  are  key  risk  factors  for  hepati-
is  B  virus  (HBV)-related  hepatocellular  carcinoma  (HCC).1,2
dditionally,  important  viral  and  host-related  factors  (geno-
ype,  HBV  mutants,  high  HBV  viral  load,  serum  hepatitis
 surface  antigen  [HBsAg]  levels,  older  age,  male  gender,
xcessive  alcohol  intake  and  possibly  metabolic  syndrome)
ay  affect  the  risk  of  HCC  development.3--5 Long-term  ther-
py  with  nucleos(t)ide  analogs  (NUC)  has  improved  the
verall  outcome  of  chronic  hepatitis  B  (CHB)  and  resulted  in
 signiﬁcant  reduction  in  the  need  for  liver  transplantation.6
reatment  with  the  third  generation  NUCs  (entecavir  and
enofovir)  causes  complete  suppression  of  viral  replication
n  more  than  95%  of  the  patients,  with  increased  rates
f  hepatitis  B  e  antigen  (HBeAg)  seroconversion  (in  HBeAg
ositive  patients)  and  improved  liver  histology  including
eversal  of  histological  cirrhosis  in  most  cases.7--11 However,
ntiviral  therapy  reduces  but  does  not  eliminate  the  risk  of
CC  in  CHB  patients  with  or  without  cirrhosis.  In  fact,  evi-
ence  of  the  effect  of  antiviral  therapy  on  clinical  outcomes
ncluding  HCC  related-incidence  and  mortality  is  weak,  as
emonstrated  in  a  recent  systematic  review  and  meta-
nalysis.12 Most  of  the  published  data  about  the  effect  of
UCs  on  HCC  risk  are  derived  from  older  prospective  cohort
nd  case--control  studies  using  lamivudine  or  interferon.
o
m
yegarding  high-genetic  barrier  NUCs,  most  of  the  available
ata  involve  patients  treated  with  entecavir  (ETV),  with  ini-
ial  reports  regarding  the  effect  of  ETV  being  reported  by
ampertico  et  al.13 This  Italian  study  demonstrated  that  CHB
atients  with  compensated  cirrhosis  and  a  persistently  unde-
ectable  serum  HBV  DNA  during  5  years  of  ETV  monotherapy
ad  an  annual  rate  of  HCC  incidence  of  2.5%,  which  is  almost
he  same  risk  that  had  been  reported  in  untreated  HBeAg-
egative  European  patients.  Retrospective  and  prospective
bservational  cohort  studies  that  provide  HCC  data  for  CHB
atients  mainly  treated  with  tenofovir  disoproxil  fumarate
TDF)  are  lacking.  Until  recently,  the  limited  data  on  the  risk
f  HCC  following  the  treatment  of  CHB  patients  with  TDF
ere  obtained  from  the  roll  over  study  of  registration  tri-
ls  in  HBeAg-positive  (GS-US-174-0103)  and  HBeAg-negative
GS-US-174-0102)  patients.14 Buti  et  al.  reported  that  the
ncidence  of  HCC  in  152  patients  with  cirrhosis  and  482
ith  CHB  treated  with  TDF  for  5  years  was  only  3.3%  and
.5%,  respectively  (annual  incidence:  0.7%).15 Two  recent
tudies,14,16 found  that  TDF  reduced  HCC  incidence  com-
ared  to  the  predicted  HCC  risk  using  the  Risk  Estimation  for
epatocellular  Carcinoma  in  Chronic  Hepatitis  B  (REACH-B)
alculator.
We  performed  a  real-life  single-center  retrospective
bservational  cohort  study  of  120  CHB  Portuguese  patients
ainly  treated  with  TDF.  Univariate  and  multivariate  anal-
sis  (Cox  proportional  hazards  regression)  of  risk  factors
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associated  with  HCC  development  were  performed.  Accu-
racy  of  a  HCC-risk  score  (REACH-B)  at  baseline  was
assessed.17,18
2. Patients and methods
2.1.  Study  population,  clinical  and  laboratory
evaluation
We  included  consecutive  patients  with  CHB  who  were
treated  with  tenofovir  or  entecavir  for  at  least  12  months
in  Centro  Hospitalar  Lisboa  Ocidental  (Hospital  Egas  Moniz,
Hospital  Santa  Cruz  and  Hospital  São  Francisco  Xavier)  --
a  tertiary  referral  center  (catchment  population  ∼993  000
individuals)  --  from  January  2006  to  February  2014.  All
patients  had  a  positive  HBsAg  for  at  least  6  months.  Exclusion
criteria  were  as  follows:  less  than  12  months  on  NUC  ther-
apy  (n  =  13),  pre-existing  HCC  or  HCC  diagnosed  within  the
ﬁrst  year  of  NUC  therapy  (n  =  5),  coinfection  with  hepatitis
D  virus,  hepatitis  C  virus  (n  =  6)  and/or  human  immunode-
ﬁciency  virus  (n  =  6)  --  see  Fig.  1  for  ﬂow-chart  of  study
cases  selection.  Data  were  collected  retrospectively  from
the  medical  records,  either  on  paper  or  electronic  charts.
HBV  DNA  was  measured  by  TaqMan  (Roche  Diagnostics)  real-
time  polymerase  chain  reaction  assay  with  a  linear  range  of
detection  from  20  to  1.7  ×  108 IU/mL.  Alanine  aminotrans-
ferase  (ALT)  serum  levels  were  measured  biannually,  normal
range  for  our  laboratory  is  between  21  and  72  U/L.  Patients
were  retrospectively  followed  since  CHB  diagnosis  until  the
end  of  follow-up  or  HCC  occurrence  (duration  of  follow-up)
and  since  NUC  therapy  start  until  the  end  of  follow-up  or  HCC
occurrence  (time  on  NUC  therapy).  Cirrhosis  was  deﬁned
by  ultrasonographic  ﬁndings  (shrunken  small  liver  with  a
nodular  surface),  clinical  and  laboratorial  ﬁndings  compat-
ible  with  portal  hypertension  (e.g.,  ascites,  splenomegaly,
gastroesophageal  varices,  thrombocytopenia).  Cirrhotic  and
non-cirrhotic  patients  with  clearly  deﬁned  risk  factors  (such
as,  African  patients  over  20  year-old,  Asian  male  patients
over  40  years-old  or  female  over  50  years-old,  patients  with
family  history  of  HCC)  were  followed  by  abdominal  ultra-
sound  and  serum  measurement  of  alfa-phetoprotein  every  6
N=150 on NUC
therapy (Jan. 2006 -
Feb. 2014) 
N=120 in study
cohort 
N=111 HCC-free N=9 HCC cases
N=30 Excluded
- Follow-up<1 year (n=13)
- HCC development
before or within 1st year
 of starting NUC (n=5)
- HCV co-infection (n=6)
- HIV co-infection (n=6)     
Figure  1  Flow-chart  of  studied  cohort  population  with
chronic  hepatitis  B  virus  infection  treated  with  nucleos(t)ide
analog  therapy  including  the  number  of  patients  who  developed
HCC during  the  follow-up.
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onths,  as  recommended  by  guidelines.19 Excessive  alcohol
ntake  was  deﬁned  as  a  daily  intake  of  >25  g/alcohol.  Total
irological  response  was  deﬁned  as  undetectable  HBV  DNA
t  3  or  6  months  under  antiviral  therapy.  Partial  virologi-
al  response  was  deﬁned  as  a  decrease  in  HBV  DNA  level
f  more  than  1  log10 IU/mL  (but  still  detectable)  after  6
onths  of  therapy.  Biochemical  response  was  deﬁned  as  nor-
alization  of  ALT  levels  at  any  time  during  follow-up.  The
EACH-B  score  consists  of  ﬁve  parameters:  gender,  age,  ALT
evel,  HBeAg  status  and  HBV  DNA  level;  it  ranges  from  0  to
7  points.17 After  exclusion  of  baseline  cirrhotic  patients,
EACH-B  score  was  calculated  at  baseline,  when  patients
egan  treatment.  Cutoff  values  of  8  and  12  points  were
sed  to  predict  risks  of  HCC.  The  primary  outcome  of  this
tudy  was  HCC  occurrence  as  deﬁned  by  international  soci-
ties  guidelines.19 Approval  for  this  study  was  obtained  from
ur  institutional  ethics  committee  --  Comissão  de  Ética  para
 Saúde,  Centro  Hospitalar  de  Lisboa  Ocidental  (complying
ith  the  Treaty  of  Helsinki).  All  study  participants,  or  their
egal  guardian,  provided  informed  written  consent  prior  to
tudy  enrollment.
.2.  Statistical  analyses
tatistical  analysis  was  performed  using  SPSS  version  20.0
SPSS  Inc.,  Chicago,  IL).  Continuous  variables  are  expressed
s  mean  ±  standard  deviation  or  median  (interquartile
ange)  as  appropriate.  Qualitative  and  quantitative  differ-
nces  between  subgroups  were  analyzed  using  2 test  or
isher  exact  test  for  categorical  parameters  and  Student
 test  or  Mann--Whitney  test  for  continuous  parameters  as
ppropriate.  In  order  to  achieve  a  comprehensive  analy-
is,  subgroup  comparisons  were  performed.  Univariate  and
ultivariate  analysis  by  Cox  proportional  hazards  regres-
ion  model  was  performed  to  identify  factors  associated
ith  HCC.  After  univariate  analysis,  variables  with  a  p  <  0.05
ntered  in  the  multivariate  analysis.  Effect  sizes  are
xpressed  as  hazard  ratios  (HRs),  adjusted  hazard  ratios
aHRs)  and  95%  conﬁdence  intervals  (CIs).  The  Kaplan--Meier
ethod  was  used  to  estimate  the  cumulative  incidence  of
CC  at  1,  3  and  5  years  on  therapy  and  differences  between
actors  were  evaluated  by  the  log-rank  test.  To  assess  the
erformance  of  the  cutoff  values  for  REACH-B  score  at  base-
ine,  we  used  the  receiver  operating  characteristic  (ROC)
urve.  The  sensitivity,  speciﬁcity,  positive  likelihood  ratio,
egative  likelihood  ratio,  positive  predictive  value  and  neg-
tive  predictive  value  of  the  different  cutoff  values  for
redicting  HCC  were  estimated  and  reported.  All  statisti-
al  tests  were  two  sided.  Statistical  signiﬁcance  was  taken
s  p  <  0.05.
.  Results
.1.  Patients’  characteristics
 summary  of  baseline  epidemiological,  clinical  and  lab-
ratorial  data  of  our  cohort  population  is  presented  in
able  1.  We  identiﬁed  120  eligible  CHB  patients  (mean
ge:  47  ±  14  years-old;  83  male;  80  Caucasian;  32  HBeAg-
ositive).  The  median  duration  of  follow-up  and  time  on
UC  therapy  was  79  months  (interquartile:  52--96)  and  39
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Table  1  Subgroup  comparison  between  non-cirrhotic  versus  cirrhotic  CHB  patients  on  antiviral  therapy  regarding  baseline  characteristics  and  HCC  prevalence.
Variable  --  n  (%)  All  patients  No-cirrhosis  Cirrhosis
All  No-HCC  HCC  p  No-HCC  HCC  p
Number  of  patients  120  103  4  8  5
Gender --  male  83  (69)  68  (66)  3  (75)  1.000  7  (88)  5  (100)  1.000
Age --  mean  ±  SD  (y/o)  47  ±  14  45  ±  14  63  ±  8  0.018  57  ±  10  65  ±  15  0.331
• Age  ≥  50  y/o  48  (40)  34  (33)  4  (100)  0.015  6  (75)  4  (80)  1.000
Duration of  follow-up  (mo)  (median;IQR)  79  (52;96)  79  (52;96)  80  (65;94)  0.733  79  (42;219)  79  (45;96)  0.754
Time on  NUC  therapy  (mo)  (median;IQR)  39  (26;54)  40  (26;55)  34  (21;48)  0.546  30  (25;33)  46  (33;49)  0.354
Tenofovir 85  (71)  75  (73)  2  (50)
0.281
5  (63)  3  (60)
1.000Entecavir 35  (29)  27  (26)  2  (50)  4  (50)  2  (40)
Ethnic origin
• Caucasian  80  (67)  68  (66)  3  (75)
1.000
6  (75)  3  (60)
1.000
• African  37  (31)  32  (31)  1  (25)  2  (25)  2  (40)
• Asian  2  (2)  2  (2)  0  (0)  0  (0)  0  (0)
• Other  1  (1)  1  (1)  0  (0)  0  (0)  0  (0)
Excessive alcohol  intake  15  (13)  8  (8)  1  (25)  0.280  3  (38)  3  (60)  0.592
HBeAg positive  (n  =  115)  32  (29)  27  (26)  0  (0)  0.570  3  (38)  2  (40)  1.000
HBV DNA  baseline  (log10IU/mL)
(median;IQR)
1790  (400;189  521)  1578  (337;38  458)  15  108  (526;43  593)  1.000  2551  (167;2  595  229)  923  450  (37  025;2  750  000)  0.683
Cirrhosis at  baseline  13  (11)  N/A  N/A  N/A  N/A  N/A  N/A
REACH-B baseline  (median;IQR)  (n  =  99)a 7  (5;9)  7  (4;9)  10  (8;14)  0.109  N/A  N/A  N/A
• ≥8  49  (50)  46  (47)  3  (75)  0.071  N/A  N/A  N/A
• ≥12  14  (14)  12  (12)  2  (50)  0.004  N/A  N/A  N/A
Previous antiviral  treatment  (n  =  117)  46  (39)  42  (41)  1  (25)  0.639  2  (25)  1  (20)  1.000
Virologic response  (n  =  117)
• Total  107  (92)  92  (89)  3  (75)
0.316
7  (88)  5  (100)
1.000• Partial  10  (8)  8  (8)  1  (25)  1  (13)  0  (0)
Biochemical response  (n  =  113)
• Total  109  (97)  95  (92)  3  (75)  0.119  7  (88)  4  (80)  1.000
HBeAg seroclearance/conversion  (n  =  27)  9  (33)  8  (30)  0  (0)  1  (37)  0  (0)
HBsAg seroclearance/conversion  (n  =  95)  1  (1)  1  (1)  0  (0)  0  (0)  0  (0)
Abbreviations: CHB, chronic hepatitis B; NUC, nucleos(t)ide analog therapy; HCC, hepatocellular carcinoma; SD, standard-deviation; y/o, years-old; mo,  months; IQR, interquartile range;
HBeAg, hepatitis B e antigen; N/A, non-applicable; HBsAg, hepatitis B surface antigen.
a After excluding patients with cirrhosis at baseline.
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Figure  2  Kaplan--Meier  analysis  of  the  cumulative  incidence
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months  (interquartile  range:  26--54),  respectively.  A  total
of  13  patients  (11%)  had  a  baseline  diagnosis  of  cirrhosis.
Patients  with  cirrhosis  were  predominantly  male  (p  =  0.060),
older  (p  =  0.002)  and  had  a  higher  prevalence  of  excessive
alcohol  intake  (p  =  0.001).  Study  samples  (cirrhotic  and  non-
cirrhotic)  were  matched  regarding  duration  of  follow-up,
time  on  NUC  therapy  and  chosen  NUC,  previous  antivi-
ral  therapy,  ethnic  origin,  HBeAg  positivity,  HBV  DNA  viral
load  at  baseline,  biochemical  and  virological  response.
The  majority  of  our  population  was  treated  with  tenofovir
(n  =  85;  71%).  Seventy-one  out  of  117  (61%)  of  the  patients
were  previously  treatment-naïve.  At  the  end  of  follow-up,
9  out  of  27  (33%)  HBeAg-positive  patients  had  a  serologi-
cal  response  (HBeAg  seroclearance/seroconversion)  and  one
patient  demonstrated  HBsAg  seroclearance/seroconversion.
3.2.  Cumulative  incidence  of  HCC
At  a  median  treatment  duration  of  39  months  (∼3.3  years),
nine  patients  (7.5%)  developed  HCC.  A  slight  majority  of
patients  (ﬁve  out  of  nine  patients;  56%)  who  developed  HCC
had  underlying  cirrhosis  at  baseline.  The  calculated  cumu-
lative  incidence  rates  of  HCC  at  1,  3  and  5  years  on  NUC
therapy  were  5.1%,  7.3%  and  8.8%,  respectively,  in  the  entire
cohort.  The  cumulative  incidence  of  HCC  was  signiﬁcantly
higher  in  patients  with  cirrhosis  at  baseline  (Fig.  2).  In  the
subgroup  of  patients  without  baseline  cirrhosis,  the  cumu-
lative  incidence  rates  of  HCC  at  1,  3  and  5  years  were  3.0%,
3.0%  and  4.6%,  respectively;  in  the  subgroup  of  patients  with
baseline  cirrhosis,  the  cumulative  rates  were  23.1%,  43%  and
43%,  respectively.
3.3.  Factors  associated  with  HCC  development
Patients  who  developed  HCC  were  older  (64  ±  12  vs  46  ±  14;
p  =  0.002),  had  higher  prevalence  of  excessive  alcohol  intake
(44%  vs  10%;  p  =  0.015),  higher  prevalence  of  cirrhosis  at
baseline  (56%  vs  7%;  p  =  0.001)  and  higher  REACH-B  scores  at
baseline  (median  12  points  vs  8  points;  p  =  0.002)  (Table  1).
On  univariate  analysis,  age,  excessive  alcohol  intake  and
cirrhosis  at  baseline  were  associated  with  subsequent  devel-
opment  of  HCC  as  seen  in  Table  2.  On  multivariate  analysis,
after  adjusting  for  gender  and  time  on  NUC  therapy,  age
(aHR:  1.085;  95%CI:  1.021--1.153;  p  =  0.009)  and  cirrhosis  at
baseline  (aHR:  13.857;  95%CI:  1.105--20.734;  p  =  0.036)  were
independent  predictors  for  HCC  occurrence.  Among  the  non-
cirrhotic  subgroup  (Table  1),  patients  who  developed  HCC
were  older  (63  ±  8  vs  45  ±  14;  p  =  0.018).  On  univariate  and
multivariate  analysis  (Table  2),  age  and  a  lack  of  biochemi-
cal  response  to  antiviral  therapy  were  associated  with  HCC
occurrence.  In  the  cirrhotic  subgroup,  there  were  no  risk
factors  for  HCC  occurrence.
3.4.  Performance  of  REACH-B  HCC  risk  score  at
baselineTable  3  and  Fig.  3  show  the  AUC  and  diagnostic  per-
formance  of  baseline  REACH-B  score  for  HCC  prediction
among  the  non-cirrhotic  population  (n  =  107).  The  AUC
was  0.738  (95%CI:  0.521--0.955)  for  REACH-B  score  at
c
o
p
Hf HCC  in  patients  according  to  baseline  cirrhosis  status  (log-
ank <0.001).
aseline.  At  a  cutoff  value  of  8  points,  the  REACH-B  score
ad  75%  sensitivity  (three  of  four  HCCs  identiﬁed)  and
1.6%  speciﬁcity  (49  of  95  patients  without  HCC  classiﬁed
n  the  low-risk  group)  to  predict  HCC  during  the  follow-up
eriod.  In  the  subgroup  of  non-cirrhotic  population  previ-
usly  treatment-naïve  (n  =  58),  the  obtained  AUC  was  0.615
95%CI:  0.293--0.937).
.  Discussion
hronic  hepatitis  B  is  a  major  cause  of  cirrhosis  and  hepa-
ocellular  carcinoma  worldwide,  being  responsible  for  1
illion  deaths  per  year.20 The  risk  of  CHB  progression  to
CC,  albeit  not  being  totally  eliminated,  might  be  reduced
y  antiviral  therapy,21 therefore,  the  identiﬁcation  and
lassiﬁcation  of  patients  who  are  at  increased  risk  of  devel-
ping  HCC  is  important.  Several  HBV  risk  scores  have  been
ublished  so  far.22--25 The  REACH-B  (Risk  Estimation  for
epatocellular  Carcinoma  in  Chronic  Hepatitis  B)  score  is
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Table  2  Univariate  and  multivariate  analysis  of  risk  factors  associated  with  HCC  in  CHB  patients  on  antiviral  therapy.
Variables  Univariate  analysis  Multivariate  analysis
HR  95%CI  p  aHR  95%CI  p
All  patients
Gender  --  male  3.351  0.418--26.834  0.255
Age 1.112  1.049--1.180  <0.001  1.085  1.021--1.153  0.009
Age ≥50  y/o  12.555  1.569--100.456  0.017
Duration of  follow-up  0.995  0.979--1.011  0.540
Time on  NUC  therapy 0.975 0.935--1.016 0.223
Tenofovir 1.880 0.504--7.009 0.347
Ethnic  origin  -- Caucasian 0.930 0.287--3.016 0.904
Excessive  alcohol  intake  5.859  1.572--21.836  0.008  1.935  0.420--8.918  0.397
HBeAg positive  0.717  0.149--3.457  0.679
HBV DNA  baseline  1.000  1.000--1.000  0.613
Cirrhosis at  baseline 13.857 3.541--54.225  <0.001  4.787  1.105--20.734  0.036
Previous antiviral  treatment 0.411 0.085--1.982 0.268
Virologic  response  --  total 0.739 0.092--5.912 0.775
Biochemical  response  -- total 0.237 0.029--1.941 0.180
No-cirrhosis
Gender  --  male  1.440  0.149--13.926  0.753
Age 1.126  1.023--1.239  0.015  1.145  1.028--1.277  0.014
Duration of  follow-up  0.999  0.977--1.021  0.926
Time under  NUC  0.963  0.901--1.029  0.264
Tenofovir  2.686  0.377--19.123  0.324
Ethnic origin  --  Caucasian  0.677  0.085--5.364  0.712
Excessive  alcohol  intake  3.567  0.370--34.414  0.271
HBeAg positive  0.029  0.000--268.931  0.447
HBV DNA  baseline  1.000  1.000--1.000  0.638
REACH-B  baselinea 1.314  0.975--1.771  0.073
• ≥8  2.968  0.308--28.588  0.346
• ≥12 6.655  0.937--47.287  0.058
Previous antiviral  treatment 0.457 0.047--4.393  0.497
Virologic  response  --  total 0.282 0.029--2.723 0.274
Biochemical  response  --  total 0.086 0.009--0.836  0.034  0.008  0.000--0.686  0.034
Cirrhosis
Gender --  male  24.250  0--7.3  ×  106 0.620
Age 1.048  0.968--1.136  0.249
Duration of  follow-up  0.990  0.971--1.009  0.281
Time under  NUC  1.003  0.952--1.058  0.908
Tenofovir  0.814  0.134--4.952  0.823
Ethnic origin  --  Caucasian  2.542  0.404--15.997  0.320
Excessive  alcohol  intake  2.370  0.391--14.366  0.348
HBeAg positive  1.287  0.213--7.758  0.783
HBV DNA  baseline  1.000  1.000--1.000  0.691
Previous antiviral  treatment  0.640  0.071--5.775  0.691
Virologic  response  --  total 24.250  0.000--7.3  ×  106 0.620
Biochemical  response  --  total  24.422  0--2.6  ×  107 0.652
Abbreviations: HCC, hepatocellular carcinoma; CHB, chronic hepatitis B; HR, hazard ratio; aHR, adjusted hazard ratio -- adjusted for
ld; N
a
b
t
f
c
3
L
tgender and time under NUC; CI, conﬁdence interval; y/o, years-o
a After excluding patients with cirrhosis at baseline.
 simple  score,  involving  non-invasive  parameters  and  has
een  externally  validated.17 It  is  useful  to  assess  the  long-
erm  risk  of  HCC  development  at  3,  5  and  10  years  of
ollow-up.  This  risk-prediction  score  was  derived  from  the
ommunity-based  Taiwanese  REVEAL-HBV  study  (a  cohort  of
584  patients)  without  cirrhosis  and  no  antiviral  treatment.
r
H
wUC, nucleos(t)ide analog therapy; HBeAg = Hepatitis B e antigen;
ater,  Wong  et  al.  demonstrated  that  REACH-B  score  main-
ained  its  predictive  power  in  patients  on  antiviral  therapy.18
In  the  present  study,  we  aimed  to  assess  HCC  incidence,
isk  factors  and  the  performance  of  REACH-B  in  predicting
CC  development  in  a  Portuguese  population  (107  patients
ithout  cirrhosis)  with  CHB  treated  with  NUCs  (71%  with
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Table  3  AUC  and  diagnostic  performance  of  baseline  REACH-B  score  for  HCC  in  CHB  patients  on  antiviral  therapy.
Cutoff  No-cirrhosisa No-cirrhosis  treatment-naïve
8  12  8
Value  95%CI  Value  95%CI  Value  95%CI
AUC  0.738  0.521--0.955  0.615  0.293--0.937
Sensitivity (%) 75.0  20.3--95.9 50.0  8.3--91.7 66.7  11.6--94.5
Speciﬁcity (%) 51.6  41.1--61.9 87.4  79--93.3 56.4  42.3--69.7
PPV (%)  6.1  1.4--16.9  14.3  2.2--42.8  7.7  1.2--25.2
NPV (%)  98.0  89.3--99.7  97.7  91.7--99.7  96.9  83.7--99.5
LR+ 1.55  0.9--2.8  3.9  1.3--12.1  1.53  0.65--3.59
LR− 0.48  0.1--2.7  0.57  0.2--1.5  0.59  0.12--2.98
No. in  high  risk  49  14  26
No. in  low  risk  50  85  32
Correct prediction  3/4  2/4  2/3
Correct exclusion  49/95  83/95  31/55
Abbreviations:  AUC, area under the ROC curve; HCC, hepatocellular carcinoma; CHB, chronic hepatitis B; CI, conﬁdence interval; PPV,
positive predictive value; NPV, negative predictive value; LR+, positive
a Includes treatment-naïve and treatment-experienced patients.
TDF).  The  estimated  prevalence  of  this  infection  in  the  Por-
tuguese  population  is  approximately  1%,  which  is  relatively
low,26,27 however,  there  is  no  doubt  that  HCC  incidence  in
Portugal  is  on  the  rise  and  its  associated  mortality  and  costs
are  high.28 In  this  retrospective  cohort  study,  with  a  median
time  on  NUC  therapy  of  39  months  (∼3.3  years),  9  out  of
120  (7.5%)  patients  developed  HCC,  which  is  similar  to  the
rate  reported  by  Yang  et  al.29 Among  patients  without  cirrho-
sis,  four  developed  HCC  (3.7%),  which  is  similar  to  the  rates
reported  by  Wong  et  al.18 and,  recently  by  Arend  et  al.30 The
incidence  and  clinical  presentation  of  HCC  in  CHB  patients
differs  signiﬁcantly  by  country  and  ethnic  origin.  In  west-
ern  countries,  HBV  related  HCC  is  clearly  associated  with
cirrhosis  and  excessive  alcohol  intake,31 whereas  in  Asia
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Figure  3  The  AUC  of  REACH-B  score  at  baseline  to  predict
HCC.
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a likelihood ratio; LR−,  negative likelihood ratio.
nd  sub-Saharan  Africa,  HCC  can  develop  in  carriers  with
ild  liver  ﬁbrosis  due  to  the  long  standing  infection  usu-
lly  acquired  at  birth.32,33 Our  ﬁndings  corroborate  data
rom  Italy  and  Greece31,34 as  on  multivariate  analysis,  the
ndependent  predictors  for  HCC  development  despite  NUC
herapy  were  older  age  (aHR:  1.085;  95%CI:  1.021--1.153;
 =  0.009)  and  cirrhosis  at  baseline  (aHR:  4.787;  95%CI:
.105--20.734;  p  =  0.036).
In  the  non-cirrhotic  CHB  patients  of  our  study  sample,
ultivariate  analysis  found  that  older  age  (aHR:  1.145;
5%CI:  1.028--1.277;  p  =  0.014)  and  a  lack  of  biochemi-
al  response  to  antiviral  therapy  (aHR:  124.046;  95%CI:
.457--10559.174;  p  =  0.034)  were  associated  with  HCC
ccurrence,  which  is  supported  by  a  very  recent  meta-
nalysis35 where  age  and  the  proportion  of  patients  with
levated  ALT  levels  predicted  the  incidence  of  HCC.  Among
he  cirrhotic  population  there  were  no  risk  factors  iden-
iﬁed.  This  is  evidence  that  age  might  be  an  important
isk  factor  only  in  non-cirrhotic  patients,  whereas,  cirrhosis
tself  is  such  a strong  risk  factor  that  it  is  seldom  inﬂu-
nced  by  other  co-factors  (namely  age)  in  the  development
f  HCC.  However,  we  cannot  ﬁrmly  conclude  that  because,
s  demonstrated  in  Table  1,  our  cirrhotic  patients  were  sig-
iﬁcantly  older  at  baseline  than  the  non-cirrhotic  cohort  and
ue  to  small  cirrhotic  sample  size  (n  =  13).
Using  Kaplan--Meier  method  (Fig.  2) we  observed  that
atients  with  cirrhosis  at  baseline  had  a  signiﬁcantly  higher
umulative  incidence  of  HCC  (log-rank  test  <0.001).  Despite
ot  reaching  statistical  signiﬁcance,  similarly  to  Wong
t  al.,18 in  our  study,  previous  antiviral  treatment  conferred
 modest  protective  effect  (HR:  0.411;  95%CI  0.085--1.982;
 =  0.268)  against  HCC  occurrence  (Table  2).
The  need  for  development  of  HCC  risk  scores  is  under-
ined  by  the  knowledge  that  NUC  therapy  cannot  completely
liminate  the  risk  of  HCC  and  that  the  identiﬁcation  of  high
isk  patients  might  lead  intensive  HCC  surveillance  strate-
ies  and  early  detection  of  HCC  and  thus  to  a  greater  chance
f  curative  treatment  with  improved  survival.36 In  our  study,
t  a median  time  on  therapy  of  3.3  years,  the  baseline
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EACH-B  AUC  obtained  for  prediction  of  HCC  development
0.738;  95%CI:  0.521--0.955)  was  lower  than  the  original  and
alidation  study  of  Yang  et  al.17 (AUC  for  predicting  3-year
CC  risk  of  0.811;  95%CI:  0.790--831)  but  similar  to  that
btained  by  Wong  et  al.18 (AUC  for  predicting  5-year  HCC
isk  of  0.71;  95%CI:  0.62--0.81).  The  cutoff  value  of  8  points,
ielded  a  sensitivity  of  75%,  speciﬁcity  of  51.6%,  positive
redictive  value  of  6.1%  and  negative  predictive  value  of
8%,  which  is  similar  to  the  results  of  the  study  by  Wong
t  al.18 Also,  in  parallel  with  the  aforementioned  study,  the
erformance  of  the  baseline  REACH-B  risk  score  in  our  sub-
roup  of  previously  treatment-naïve  patients  was  slightly
nferior  (Table  3).  Our  data  highlights  and  conﬁrms  the  major
rawbacks  of  this  risk  score,  which  is  its  high  false-positive
ate,  making  it  unable  to  correctly  identify  low-risk  patients,
s  only  49  out  of  95  patients  without  HCC  were  classiﬁed  in
he  low-risk  group.  This  might  be  due  to  the  fact  that,  as
n  the  original  study,  in  our  patients,  cirrhosis  was  ruled  out
y  ultrasound  only.  Another  possible  limitation  of  this  risk
core  was  described  by  Kim  et  al.14 Using  a  population  mainly
omposed  of  TDF  treated  patients  from  the  roll-over  stud-
es  of  registration  trials,  the  real  incidence  of  HCC  and  the
ncidence  predicted  based  on  the  REACH-B  score  was  eval-
ated.  The  authors  found  that  after  3.3  years  there  was  a
rogressive  divergence  between  the  predicted  (by  REACH-B
core)  and  the  observed  number  of  HCC  cases.  Most  stud-
es  addressing  HCC  occurrence  during  NUC  therapy  do  not
xceed  4--5  years,  so  it  remains  to  be  established  if,  with
onger  time  on  NUC  therapy,  HCC  incidence  remains  stable.
ence,  our  data  demonstrate  that  REACH-B  score  has  many
imitations  especially  in  Caucasian  populations,  with  AUC  of
.738,  using  Harrell’s  c-index,  it  is  considered  as  of  modest
iagnostic  accuracy  only.  This  considerably  limits  the  utility
f  the  score.
In  clinical  practice,  patients  at  increased  baseline  HCC
isk  should  continue  to  undergo  regular  HCC  surveillance
ccording  to  published  guidelines,19 however,  enhancing  this
ecommendations  with  the  addition  of  predictive  risk  scores
REACH-B)  may  identify  additional  patients  at  higher  risk
f  developing  HCC  (REACH-B  score  at  baseline  ≥8  points)
nd  who  would  thus  beneﬁt  from  HCC  surveillance  strate-
ies.  Accordingly,  patients  at  higher  risk  for  HCC,  despite
eing  on  antiviral  therapy,  should  undergo  HCC  surveillance.
otwithstanding,  we  must  note  that  there  is  recent  evidence
emonstrating  that  a  higher  HCC  detection  might  not  lead
o  a  reduced  HCC-related  mortality.35
Another  possible  application  for  the  REACH-B  score  could
e  the  indication  for  antiviral  treatment  initiation,  as  shown
n  a  recent  study,37 where  the  authors  demonstrated  that
he  discriminatory  performance  of  the  REACH-B  score  in
lassifying  antiviral  treatment  eligibility  based  on  the  local
uideline  (APASL  2012)  was  good/excellent  with  the  excep-
ion  of  older  HBeAg-positive  patients.
Our  study  has  some  limitations,  especially  data  regarding
he  cirrhotic  cohort.  It  is  evident  that  the  cumulative  inci-
ence  of  HCC  in  cirrhotics  was  considerably  high,  exceeding
ost  of  previous  reports  of  the  South-European  area  (Italy,
reece,  Spain),  this  is  probably  due  to  a  small  size  of
he  sample.  Also,  most  of  the  HCC  cases  in  the  cirrhotic
ohort  cumulate  in  the  ﬁrst  months  of  therapy,  suggesting
 selection  bias.  The  diagnosis  of  cirrhosis  was  based  on
linical,  laboratorial,  radiological  and  endoscopic  features
P
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liver  biopsy  was  not  available  for  the  non-cirrhotic  popu-
ation).  Hence,  patients  with  histological  or  early  cirrhosis
ight  have  been  unrecognized.  Even  with  a  long  follow-
p,  due  to  a  relatively  small  and  rather  heterogeneous
ohort  sample  and  the  low  number  of  events,  our  estima-
ion  of  the  accuracy  of  REACH-B  risk  score  was  limited.
nother  important  limitation  of  our  study  is  related  to  the
act  that  REACH-B  score  was  originally  derived  from  an
sian  population.  Additionally,  HBsAg  levels  quantiﬁcation,
hich  is  a  novel  marker,  known  by  its  high  reproducibility
nd  low  cost,  is  currently  not  available  in  our  institution.
n  fact,  a link  between  HBsAg  levels  and  HCC  was  ﬁrst
stablished  by  the  ERADICATE-B  cohort  study.38 As  a  con-
equence,  the  original  REACH-B  risk  calculator  (known  to
nderestimate  the  risk  in  patients  with  very  low  viral  load
t  baseline)  as  suffered  two  major  recent  upgrades  (using
sian  cohorts  only)  in  order  to  maximize  its  accuracy  in  pre-
icting  HCC  occurrence.  The  most  robust  and  costly  REACH-B
Ia,  that  incorporates  the  original  factors  plus  HBV  DNA  and
BsAg  levels  quantiﬁcation39 and  the  cheapest  REACH-B  IIb,
hich  incorporates  the  original  factors  plus  HBsAg  levels
uantiﬁcation.40 Both  upgraded  risk  calculators  need  further
ost-effectiveness  evaluation  and  external  validation.5 The
iagnosis  of  cirrhosis  based  on  regular  imaging  and  clinical
arameters  can  be  imprecise.  Hence,  recent  developments
n  non-invasive  tests  of  liver  ﬁbrosis  may  further  improve
he  risk  prediction.  In  fact,  in  a  study  performed  by  Lee  and
oworkers,  the  addition  of  liver  stiffness  measurement  (by
ransient  elastography)  to  REACH-B  improved  the  diagnostic
ccuracy  to  predict  liver-related  events  when  compared  to
EACH-B  score  alone.39 Very  recently,  another  risk  score  was
eveloped  by  Papatheodoridis  and  coworkers  in  a  large  mul-
icenter  study  in  1619  Caucasian  European  patients  under
UC  therapy  (entecavir  and  tenofovir),  the  PAGE-B.40 The
ariables  included  in  this  risk  score  are:  age,  gender  and
latelet  counts.  This  risk  score  appears  to  be  very  simple  and
robably  the  most  suitable  HCC  risk  predictor  in  Caucasian
atients  receiving  antiviral  therapy.
. Conclusion
n  conclusion,  continued  HCC  surveillance  is  recommended
or  CHB  patients  on  antiviral  therapy.  Age,  excessive  alcohol
ntake  and  cirrhosis  remain  as  the  most  important  risk  fac-
ors  associated  with  HCC  onset  in  CHB  patients  on  antiviral
herapy.  REACH-B  score  has  many  limitations,  especially  in
aucasian  populations.  With  an  AUC  of  0.738  it  is  considered
s  of  modest  diagnostic  accuracy  and  this  considerably  limits
he  utility  of  the  score.  This  is  the  ﬁrst  study  assessing  the
tility  of  the  REACH-B  HCC-risk  score  in  Portugal.  Prospec-
ive  studies  using  larger  samples,  longer  follow-up  periods
n  antiviral  treatment  and  the  use  of  non-invasive  measure-
ent  of  liver  stiffness  will  be  particularly  useful  in  order
o  clarify  the  best  algorithm  for  HCC  surveillance  in  CHB
atients  under  nucleos(t)ide  analogs  therapy.
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